Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
“Castle is committed to our mission--improving health through innovative tests that guide patient care,” said Derek Maetzold, president and chief executive officer of Castle Biosciences and IMPACT Melanoma board member. “We are grateful for the opportunity to ring the closing bell in honor of patients with melanoma, their families and caregivers, and importantly, their clinicians, who we are privileged to partner with to help improve their care. At the end of the day, we are all working together to make an impact in people’s lives and perhaps provide something even more powerful than that … hope for the future.”
- “Castle is committed to our mission--improving health through innovative tests that guide patient care,” said Derek Maetzold, president and chief executive officer of Castle Biosciences and IMPACT Melanoma board member.
- “We are grateful for the opportunity to ring the closing bell in honor of patients with melanoma, their families and caregivers, and importantly, their clinicians, who we are privileged to partner with to help improve their care.
- IMPACT Melanoma is the nation’s leading non-profit dedicated to significantly reducing the incidence of melanoma in the United States and saving lives.
- The live broadcast will begin at 3:50 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York.